Heart failure and cancer: From active exposure to passive adaption

Yantao Du¹ and Tao Wu²*

¹Ningbo Institute of Medical Science, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, Zhejiang, China; ²Department of Cardiovascular Center, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, Zhejiang, China

The human body seems like a “balance integrator.” On the one hand, the body constantly actively receives various outside stimuli and signals to induce changes. On the other hand, several internal regulations would be initiated to adapt to these changes. In most cases, the body could keep the balance in vitro and in vivo to reach a healthy body. However, in some cases, the body can only get to a pathological balance. Actively exposed to unhealthy lifestyles and passively adapting to individual primary diseases lead to a similarly inner environment for both heart failure and cancer. To cope with these stimuli, the body must activate the system regulation mechanism and face the mutual interference. This review summarized the association between heart failure and cancer from active exposure to passive adaption. Moreover, we hope to inspire researchers to contemplate these two diseases from the angle of overall body consideration.

KEYWORDS
heart failure, cancer, active exposure, passive adaption, Cardio-Oncology

Introduction

The most hazardous and complicated diseases are heart failure and cancer. So far, clinical and basic researchers have formed theoretical principles and related treatments for each disease. However, according to epidemiology studies, heart failure and cancer coexist in a similar population. Although not very comprehensive, the new emerging Cardiac-Oncology has been set up to mainly focus on the heart toxic during the anti-cancer treatment process. Many reviews have given excellent summaries about their associations from the co-incidence, similar risk factors, and correlated regulation mechanisms, which indicated some underlying clues for both diseases (1, 2). Considering each individual as a whole study subject, heart failure and cancer are different manifestations of physical problems but can originate from similar physical backgrounds.

Heart failure and cancer populations tend to actively expose themselves to similar lifestyles or have to adapt to their pre-existing physical condition (Figure 1). These stimulations may disturb the primary balance of the individual. They will activate several regulation systems to amend those unbalance,
even though some are not physical but pathological, such as the neuroendocrine system, immune system, gut microbiome, and intercellular communication via various cytokines and molecules. Furthermore, both could produce mutual interference during their progression and drug treatment. Our review aims to focus on these two diseases and summarize their correlation from active exposure to passive adaptation.

Active exposure

An unhealthy lifestyle leads to a vast significant influence on the incidence of cardiovascular (CV) diseases and cancer. Unfortunately, many unhealthy lifestyles exist for humans, such as smoking, alcohol addiction, lack of physical exercise, loss of sleep, and poor diet.

Smoking is an essential factor for heart failure and various cancers. On the one hand, tobacco increases the risk of heart failure (HF) by coronary artery disease-dependent mechanisms (3). Continued smoking deteriorates the prognosis of patients with HF, while suspending smoking could decrease the risk of major adverse cardiac events (3). On the other hand, smoking has essential effects on various kinds of cancers, such as lung cancer (4), breast cancer (5), cervical cancer (6), and liver cancer (7). The mechanisms involve several secondary toxicities of tobacco, including irritants, carcinogens, pro-inflammatory stimuli, and oxidizing agents (8). Among them, nicotine contributes to the pathogenesis of CV diseases and cancer (9, 10). It could directly depress apoptosis and promote angiogenesis (8). Likely, smoking-related cancer is also prevalent in patients with CV diseases (11).

Although low-to-moderate alcohol consumption might be beneficial for cardiac function, a chronically large quantity of ethanol consumption is toxic to the heart and vascular, even progressing to heart failure (12). In addition, pre-existing cardiovascular diseases may be deteriorated by alcohol abuse, such as hypertension and cardiomyopathy. Again, about 4% of cancer in the global world is caused by alcohol consumption (13). In addition, it could increase the risk of digestive system cancer and sex-related cancer, such as breast
Physical activity has been widely studied as a protection factor for HF patients. Exercise can provide primary prevention for past onset HF and secondary prevention for present HF and can also be used as a prognostic factor for predicting the future of HF patients (14). A meta-analysis result indicated that high levels of total physical activity, leisure-time activity, vigorous activity, occupational activity, walking and bicycling combined, and cardio-respiratory fitness could reduce the risk of heart failure (15). As a comparison, in cancer, a systematic review compared the highest to lowest physical activity levels and summarized that approximately 10–20% risk reduction could be reached in bladder, breast, colon, endometrial, esophageal adenocarcinoma, renal, and gastric cancer (16). Again, according to 18 systematic reviews and meta-analyses, a great deal of physical activity could reduce 40–50% risk of all-cause and cancer-specific mortality in patients with breast, colorectal, or prostate cancer (16). About 40% reduction in cancer incidence and cancer-related death is benefited from increased physical activity (17).

Sleep loss could also result in harmful outcomes, including heart diseases, certain cancers, and all-cause mortality (18–22). According to the data from the health and retirement study in the United States, insomnia symptoms, both cumulatively and individually, are associated with incident HF (23). Sleep loss is also related to various kinds of cancer, such as neck and head cancer (24), prostate cancer (25), and malignant brain tumor (26). Michael et al. reported that sleep loss might activate spontaneous cellular innate immunity (27). They hypothesize that treatments for short sleep duration have the potential to inhibit inflammation and decrease the risk for inflammatory disorders and some cancers in humans (27).

The habit of diet is also crucial for people. Poor diet is present in different ways and contexts. As we all know, some familiar diet habits could cause acute injury and chronic toxicity to the human body. For example, hot food would break down the esophageal mucosa and cause esophageal cancer (28), while moldy food would produce aflatoxin and be associated with liver cancer (29). Furthermore, some new evidence indicated the interaction between diet habits and the human body. For example, an excessive high-fat diet (HFD) would induce toxicity to the heart in rats by promoting cardiac injury biomarker leakage into plasma and altering heart rate and electrocardiogram pattern, as well as plasma ion levels (30). In addition, HFD could induce apoptosis and inflammation in rat hearts, which was supported by detecting higher expression levels of Bax and caspase-3 and a large amount of cardiac cellular DNA fragmentation (30). Similarly, HFD could induce colorectal tumorigenesis by destroying the gut barrier and leading to dysregulation of microbial and metabolomic (31). Besides, excessive intake of red meat is related to cancer and heart failure. According to an umbrella review, red meat consumption was related to a growing risk of overall cancer mortality, including non-Hodgkin lymphoma (NHL), bladder, breast, colorectal, endometrial, esophageal, gastric, lung, and nasopharyngeal cancer (32). A cohort study that involved 29,682 participants found that excessive intake of processed red meat, unprocessed red meat, and poultry, but not fish, was significantly associated with exposure to cardiovascular diseases and all-cause mortality (33). On the contrary, healthy diet patterns could reduce cancer and heart failure incidence, like adequate blood sugar control decreases the incidence of CV disease and cancer (34). Several famous healthy diet patterns could prevent HF. For example, Dietary Approaches to Stop Hypertension (DASH) advocates high potassium and low sodium, sulforaphane (SFA), and total fat (35), while MedDiet (Mediterranean) stresses more unsaturated fatty acids (UFA) (36), which are rich mainly in antioxidants and anti-inflammatory nutrients, and offers a solid and inverse correlation with cardiovascular diseases (37). MedDiet and DASH diets are particularly rich in plant-based foods but limited in processed foods and red meat (38).

**Passive adaption**

**Basic diseases: Acceptation of imperfections**

Various chronic diseases would force the human body to passively adopt these changes and create a unique background for populations with different diseases.

For the terms of heart, hypertension, obesity, and diabetes mellitus (DM) are harmful to vascular and metabolism, which would finally lead to heart failure (39–47). These changes often start with different interrelated processes but end with HF. Obesity and diabetes mellitus always cause damage to the vascular by inducing inflammation and atherosclerosis to increase vessel stiffness and peripheral vascular resistance because of long-term immersion in high blood fatty acid and sugar. Increased vascular resistance leads to hypertension, forms high pressure for cardiac afterload, and forces myocardial hypertrophy. Furthermore, a high concentration of blood fatty acid and sugar would increase the blood volume, which increases cardiac preload. Overall, the heart always tries to adapt to handle increased preload and afterload, but then it would not endure them, followed by decompensation, leading to heart failure. Some treatments can be used to reverse such dysfunction. For example, strict glycemic control and high-quality insulin therapy could reduce severe cardiac dysfunction in patients with diabetes mellitus (48). Besides, it is interesting that there is a paradox between obesity and HF. Obese people...
are more likely to develop HF, but they have a survival advantage (49). However, the mechanism is not very clear.

In terms of cancer, although the underlying mechanisms are not very clear, a series of reports supported the significant relationship between chronic diseases and cancer. A large prospective cohort study of over 400,000 subjects indicated that chronic diseases (CV, diabetes, chronic kidney disease, pulmonary disease, and gouty arthritis) were independently related to cancer incidence based on a regular risk score (50). Moreover, the accumulative score of chronic diseases has a dose-dependent relationship with cancer incidence and mortality (50). For example, in patients with hypertension, a 10mmHg increment in blood pressure was associated with an increased risk of cancer incidence (HR 1.07, 95% CI 1.04–1.09) in men and cancer-related mortality (HR 1.12, 95% CI 1.08–1.15 and HR 1.06, 95% CI 1.02–1.11, respectively) both in men and women (51). Obesity is associated with a chronic pro-inflammatory state, which could induce DNA damage and cancer incidence (52). Fatty tissue also plays the role of a sizeable endocrine organ, which could produce a great deal of estrogen and promotes hormone-related cancers, such as ovarian and breast cancer (53). Furthermore, adipose tissue could secrete many adipokines related to cellular survival. For example, leptin was one of the well-known adipokines with cell-proliferative effects (54), while another well-known adipokine, adiponectin, was reported to have anti-proliferative effects (54). Besides, insulin and insulin-like growth factors (IGF-1) were increased in obese subjects. High levels of IGF-1 were reported to relate to the development of cancer (55), which was hypothesized and observed to increase cancer incidence by promoting cell proliferation (56–58). Therefore, lowering weight or reducing the weight loss by surgery would reduce cancer risk (59, 60).

Systematic adjustment

Immune system: Chronic inflammation

The immune system is involved in developing cancer and HF (61, 62). Atsushi Anzai has a well-reviewed immune system in CV diseases (63). There are several stages during the HF process. In the early stage after myocardial infarction (MI), different immune cells move to the injury area and try to constrain and restore the primary damage. While in the late stage, a low grade of chronic activation could induce heart modification (64, 65). First, neutrophils rapidly move to the damaged area and activate a pro-inflammatory phase after MI. The infiltrated neutrophil population changed along with the healing process and gradually acquired surface lectin SiglecF (66). Then, macrophages infiltrate and resolute the necrotic tissue and start the process of scar formation in the coming 3–30 days. In HFpEF (heart failure with preserved ejection fraction) heart, cardiac macrophages induce myocardial cell death and interstitial fibrosis. Stefan Frantz et al. have systematically reviewed the function of macrophages in different stages of ischemic heart diseases (67). Interestingly, macrophages show heterogeneity because of their sources. CCR2+ (C-C chemokine receptor +) macrophages come from embryonic, the primary resident population in a healthy heart. However, ischemic cardiac injury induces monocyte-derived CCR2− macrophages to infiltrate the heart (68, 69). Engulfment results in increased fatty acid in macrophages, activate mitochondrial respiration, and initiate anti-inflammatory responses during the wound healing process (68, 70). The following remodeling phase will involve low-grade inflammation and non-infarcted myocardium, which are regulated by cytokines and innate immune receptors. It is a long, complicated process involving not only various kinds of immune cells but also numerous pro-inflammatory cytokines, which are increased and may contribute to the development of HF (71). Activated dendritic cells induce B- and T-cell proliferation by migrating from injury myocardium to pericardial adipose tissue fat-associated lymphoid clusters (FALCs) (66, 68). In response to acute injury of the heart, a group of innate B cells within FALCs expressed a considerable amount of granulocyte-macrophage colony-stimulating factor (GM-CSF), induced interleukin-23 (IL23), and interleukin-17 (IL17) secreted from immune cells (66, 68). However, some regulation mechanisms play protective effects. A subpopulation of macrophages with GATA binding protein 6 (GATA6) expression could inhibit excessive cardiac fibrosis (68), while Group 2 Innate lymphoid cells (ILC2) population stimulated by interleukin-2 (IL2) expanded in pericardial adipose tissue to protect cardiac function (68).

In cancer, the abnormal immune system is also related to cancer progression and metastases (72). Currently, immune therapy focused on the immune checkpoint has obtained spectacular results (73). However, limitations were revealed by the wide use of these drugs. Targeting the tumor immune system may be at the cost of deteriorating the myocardial immune system (74). Meijers et al. reported that new-onset cancer could be predicted by high-sensitivity C-reactive protein and mid-regional pro-adrenomedullin (75).

Inflammation could also play a crossroads between CV diseases and cancer. In Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial, the interleukin-1 (IL-1) blocker canakinumab was used to test whether IL-1 inhibition could attenuate coronary events in future (76). Compared with placebo, canakinumab can reduce about 25% of major adverse CV events (HR 0.75, 95% CI 0.66–0.85) (76). More interestingly, treatment with canakinumab could also decrease the incidence of lung cancer and mortality in a significant dose-dependent manner [Incidence: HR 0.33, 95% CI 0.18–0.59, P < 0.0001; Mortality: HR 0.23, 95% CI 0.10–0.54, P = 0.0002] (77).
Oxidative stress

Oxidative stress originates from unbalancing between reactive oxygen species (ROS) generation and antioxidant defense (78). ROS can be produced through several sources (78). Among them, mitochondria produce ROS by transporting a single electron to molecular oxygen (78). Mitochondrial oxidative phosphorylation provides high energy to support the heart’s function and is involved in cancer progression (79).

In HF, Hill and Singal reported that antioxidant deficits and oxidative stress coexist in patients of HF after MI, which may affect cardiac function (80). Also, ischemia or hypoxia would induce ROS increase and be related to myocyte damage of MI (81). Because of abnormal mitochondrial metabolism in HF, glycolysis increases lactate production in a failing heart (82).

In cancer, altered mitochondrial metabolism promotes the glycolysis to adapt to the rapid proliferate tumor cells. Pyruvate dehydrogenase (PDH) and PDH kinase (PDK) are two key modulators. PDH controls the rate of glucose oxidation, while PDK inhibits PDH (82). Interestingly, PDK upregulation and PDH inhibition are in both HF and tumor cells (83). On the one hand, dichloro (a PDK inhibitor) could enhance PDH activity to lower ischemic injury and improve cardiac function. On the other hand, it could also reduce cancer development (83).

Neuroendocrine: Non-coordinated activation

As we all know, the neuroendocrine system plays the most crucial role in cardiovascular regulation. For the cardiovascular system, there are many neurohormonal pathways, firstly serving as a compensation mechanism, including the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system (SNS), and natriuretic peptides system (NPS) (Figure 2). They could be promptly activated to react to cardiovascular events when a certain balance was disrupted at a sudden time. Still, gradually chronic neuroendocrine non-coordinated activation contributes to disease progression by promoting cardiac remodeling and deteriorating heart function (84).

However, compared to the heart, local RAAS hormones and receptors differ in various cancers (85). For example, angiotensin II receptor type 1 (AT1R) increased expression during cancer progression, while Ang II/AT2R signaling exerts the opposite effect (85) (Figure 2). Over-activity of SNS may result in carcinogenesis via the β-arrestin-1 signaling pathway (86). It also could induce cell proliferation through specific molecular pathways, such as cAMP-response element binding protein (CREB), nuclear factor-κ-gene binding (NF-κB), and activator protein-1 (AP-1) (87). Besides, it confers resistance to apoptosis through various mechanisms, such as inhibition of p53 (87), proapoptotic protein BAD (bcl2 associated death promoter) (88), and anoikis (89). Because of the broad expression of β1 and β2 ARs (β1 and β2 adrenoceptor agonists) in cancer, β-blockers might be a candidate target for cancer treatment (90, 91). The SNS could also modify the cancer microenvironment (92). For example, in response to the β-adrenoceptor agonist (BAR) stimulation, tumor-associated macrophages release prostaglandin E2 and stimulate vascular endothelial growth factor C (VEGF-C) expression to increase lymph and blood vessel density (93). Moreover, the SNS could suppress natural killer cells by activating BAR activity promoting neoplasm dissemination (94). Besides, the role of natriuretic peptides in carcinogenesis has also been accessed (94). In addition, N-terminal pro-brain natriuretic peptide (NT-proBNP) has been verified to be involved in cancer progression.
and could play as a biomarker for monitoring anti-cancer drug-induced cardiotoxicity (95).

Circulation molecules: Exosome-mediated indirectly regulation

Microvesicles, especially exosomes, play an essential role in various diseases. They bring nuclear acid and protein molecules to participate in cell communication. Exosomal miRNAs are vital in diagnosis biomarkers for certain diseases because of the tissue specificity. For example, in the heart of a patient with heart failure, secreted Exo-microRNA-21-5p damages the regenerative potential of the heart (96). Exo-miR-92b-5p has also been verified as a biomarker for HF (97). In cancer, a massive amount of miRNAs not only regulate cancer progression (98) but also participate in creating the tumor microenvironment. For example, exo-miR-522 derived from cancer-associated fibroblasts inhibited ferroptosis in the cancer cell and led to chemoresistance in GC (gastric cancer) (99). For example, tumor-derived exo-miR-934 can regulate the communication between colorectal cancer cells and tumor-associated macrophages to stimulate colorectal cancer liver metastasis (100).

Because of tissue-specific differences, many kinds of circulation miRNAs were studied as biomarkers of certain diseases, such as heart failure and cancer. However, circulation exosomal miRNAs might affect the whole body. In this review, we summarized the function and mechanism for several kinds of miRNAs and tried to analyze the entire effect of specific miRNAs on both heart and cancer (Table 1).

Gut microbiome: Bidirectional regulation

The human microbiome is composed of various microorganisms (142, 143). Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria are the four main bacterial species (144). The human microbial ecosystem is not only composed of a part of the human but also positively participates in human health and disease by regulating the function of the mucosal barrier, immune state, growth of pathological organisms, and metabolism (145–149).

Accumulating evidence indicated that changes in the gut microbial community were involved in cardiovascular disease (150). Coriobacteriaceae, Erysipelotrichaceae, Ruminococcaceae (family level), and Blautia (genus level) were decreased in chronic HF (151). Eubacterium rectal and Dorea long catena from the Lachnospiraceae family (152) and Faecalibacterium from the Ruminococcaceae family were decreasing in older patients (152) and patients with HF (153). In addition, the metabolism derived from the gut is closely related to HF. In 2013, trimethylamine-N-oxide (TMAO) was first reported as a predictor of CV events (154). Decreasing butyrate and increasing TMAO have been consistently verified in heart failure (150). TMAO accumulation stimulates platelet aggregation, promotes foam cell formation, induces inflammation, and reduces reverse cholesterol transport (154–157).

In contrast, the microbiome is also related to the carcinogenesis and progression of various cancers by producing toxic metabolites or carcinogens (158). In addition, it can cause inflammation or immune suppression and indirectly lead to carcinogenesis (158). In patients with CRC, the fecal microbiota belongs to Bacteroidetes (mainly Porphyromonas and Prevotella) and Firmicutes (mainly Enterococcus and Streptococcus) (159). Helicobacter Pylori is GC-related bacteria. It can suppress macrophages and T cells via protein VacA (159) and inhibit epithelial cell apoptosis (160). Compared to the sterile stomach in healthy individuals, the gut of GC patients harbors a complex microbial ecosystem, including Proteobacteria, Firmicutes, Actinobacteria, Bacteroides, and Fusobacteriaphyla (161, 162). In liver cancer, a high-fat diet led to the enrichment of Clostridium species and accelerated the progression of liver cancer by producing excess secondary BA deoxycholic acid (163). However, growing evidence showed that bacteria could defend gastroenteric tumors by promoting the host’s anti-tumor immunity (164–167).

Researchers have observed massive data about the gut microbiome changes in certain cancers or heart failure (Figure 3). However, we lack data on cancer combined with heart failure. The gut microbiome could not only indicate the prognosis of cancer and heart failure but also have the potential as probiotics to treat the two diseases. The critical point is that the experimental design cohort should focus on combining both cancers and heart failure so that we can find out the categories and mechanisms of the particular gut microbiome and consciously adjust their component to help deal with both cancers and heart failure.

Mutual interference

The causal relationship between cancer and heart failure

Considering the angle of the individual, it is hard to distinguish the causal relationship between cancer and heart failure. Apart from cancer, infection and multi-organ failure are the second ranks of death in cancer patients (168). However, it is still unclear about the cause of death in advanced cancer (169). Anker et al. have proposed a hypothesis: "advanced cancer is also a heart failure syndrome" in their review (170). They hypothesized that cancer is related to severe tissue inflammation, oxidative stress, and local neurohormonal abnormal activation resulting in heart atrophy, increasing ventricular wall stress, and arrhythmias due to electrical instability and death (170). Furthermore, they hypothesized that heart atrophy might be the tip of the iceberg on the progression of loss of skeletal muscle mass.
| Exosomal miRNA | Functions in heart failure | Functions in cancers | Several inspired comments or predictions for the whole effects of both hearts and cancer |
|----------------|---------------------------|---------------------|-------------------------------------------------|
| miR-92b        | • miR-92b-5p increased in heart failure as a biomarker (97, 101) | • miR-92b suppressed CD69 on natural killer (NK) cells and predicted the risk of post-transplant HCC (hepato-cellular carcinoma) recurrence (102); • miR-92b was upregulated and could monitor chemoresistance in small lung cancer (103); • miR-92b decreased in early CRC (colorectal cancer) cancer (104). | • Increased circulation miR-92 in response to chemoresistance might be the toxicity of anti-cancer treatment to the heart. |
| miR-17-92 cluster (17/18a/20a/19b-1/92a-1) | • miR-19a/19b related with cardiac regeneration (105); • miR-92a increased in AHF (acute heart failure) (106); • miR-19b-3p is a biomarker for AHF (107). | • miR-17-92 cluster was related to RC (Renal Cell) cancer relapse (108); • miR-20a-5p was increased and correlated with recurrence of bladder cancer (109); • miR-17-92 cluster is increased in esophageal adenocarcinoma and is related to progression and lymph node metastasis (110); • miR-17-9p, diagnosis marker for non-small cell lung cancer (111); • Tumor-derived Exo-miR-19b-3p promotes M2 macrophage polarization and secrets Exo-LINC00273 to stimulated lung adenocarcinoma metastasis (112); • miR-19b-3p increased and biomarkers in prostate cancer (113). | • Increased miR-17-92 cluster members were related to the regeneration of heart injury and the promotion of cancer progression. • Increased miR-19b-3p inducing M2 macrophage polarization might lead to cardiac remodeling in one way and promote cancer progression. |
| miR-21         | • miR-21 could provide a diagnosis of early heart failure (114); • miR-21 was increased and related to NT-proBNP and galectin-3 levels in acute HF combined with DM (115); • miR-21 increased in response to an acute exhaustive exercise in CHF (chronic heart failure) patients (116). | • miR-21-3p is associated with angiogenesis and vascular permeability in CR (117); • miR-21 increased in NSCLC (non-small cellular lung cancer) patients as diagnosis and prognosis (118); • miR-21 increased in GC patients as a detection marker (119); • miR-21 elevated in breast cancer as an indicator (120); • miR-21 upregulated in glioblastoma as a biomarker (121); • miR-21 unregulated in RCC and decreased after surgery (122); • miR-21 upregulated in gastric cancer (123). | • miR-21 increased promptly in AHF, and sensitivity to heart function might be associated with its significant role in angiogenesis and vascular permeability, which lead to cancer metastasis and simultaneously induce heart regeneration. |
| miR-22         | • miR-22 increased in heart failure, a biomarker for AHF (106); • miR-22-5p is higher in HFE (heart failure with preserved ejection fraction) patients with AF by altering Ca2+ handling and defective cell-to-cell communication (124). | • miR-22-3p increased in NSCLC and was a biomarker for diagnosis and drug resistance prediction (125); • miR-22 was a biomarker for osteosarcoma (OS) diagnosis, prognosis, and chemosensitivity prediction (126). | • miR-22 increased circulation could damage the heart function and induce resistance to anti-cancer treatment. |
| miR-1306       | • miR-1306-5p was positively associated with adverse clinical outcomes in AHF (127). | • miR-1306-3p was negatively associated with the TNM (tumor node metastasis) stage of gastric cancer and lymphatic metastasis (128). | • miR-1306 increased indicated bad outcomes for both heart failure and gastric cancer. |
| miR-30 family (30a/30b/30c/30d/30e) | • miR-30 family members could inhibit Ang II and reduce the expression of inflammation molecules (129); • miR-30 family decreasing induced increase of CTGF (connective tissue growth factor), which could promote collagen synthesis (130); • miR-30c-5p was a biomarker for diastolic dysfunction by altering the endothelial cell metabolism and microvascular dysfunction (131). | • miR-30a decreased in osteosarcoma and contributed to chemoresistance (132); • miR-30 family inhibits breast cancer metastasis (133). | • miR-30 family might be a protective factor for anti-heart failure and cancer because its family members decreased in individuals would lead to heart remodeling and cancer metastasis. |
| miR-106a-363 cluster from X chromosome | • miR-106a was decreased in AHF (134). | • miR-106a was increased in RCC but was decreased after surgery (122); • miR-106a was increased in breast cancer (135); • miR-106a was decreased in Cholangiocarcinoma (136); • Low expression of miR-106a promotes the metastasis of prostate cancer (137). | • The expression level of miR-106 in the heart indicated that it might be involved in cardiac remodeling. Although the reports were inconsistent, according to the newest review of cancer biology (138), the proliferation of cancer cells would be postponed when metastasis started. So miR-106 might be related to tissue repair and proliferation. |
| miR-1          | • Increased in response to caudal blood treatment (139); • Downregulated in HF, a biomarker for predicting exacerbation of HF (140). | • miR-1 was related to the changes in LVEF (left ventricular ejection fraction) and could be a potential new biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients (141). | • miR-1 was sensitive to heart injury and could be a protective monitor for toxicity of cancer treatment. |
In addition, the particular point is that the cardiovascular response to cancer treatment may differ in age and sex (172–174). Large numbers of researchers have reported related heart toxicity mechanisms during anti-cancer treatment. Moreover, many reviews have well summarized this part of the section (175). We tried to list several kinds of drugs and associated mechanisms for heart failure in Table 2.

Although many side effects on the heart have been found during cancer treatment, some measures can be used to reduce these side effects. For example, empagliflozin (EMPA) could prevent doxorubicin-induced cardiotoxicity (176, 177) by inhibiting ferroptosis, fibrosis, apoptosis, and inflammation through nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) and myeloid differentiation factor 88 (MyD88)-related pathways (178). Such combined treatment is deserved to be encouraged to make more attempts.

Cancer risk and prognosis during the cardiac-related treatment

It is challenging to clarify the relationship between CV drugs and cancer risk. According to a large meta-analysis,
TABLE 2  Cancer therapy-induced heart toxicity.

| Anti-cancer therapy | Anti-cancer mechanisms                                                                 | Side effects on heart                                      |
|---------------------|----------------------------------------------------------------------------------------|------------------------------------------------------------|
| Anthracyclines      | • Inhibiting DNA replication and RNA synthesis through inhibition of topoisomerase II (179, 180);  
|                     | • Damaging DNA, proteins, and cell membrane structure by Chelating iron ions and producing free radicals (181). | • Age and dose-dependent toxicity (182, 183);               |
|                     | • Age and dose-dependent toxicity (182, 183);                                           | • Oxidative stress (181, 184, 185);                        |
|                     | • Oxidative stress (181, 184, 185);                                                    | • Inhibits fatty acid oxidation (186);                      |
|                     | • Inhibits fatty acid oxidation (186);                                                  | • Interfere cellular energetic buffering and availability of |
|                     | • Ferroptosis (188);                                                                   | cytoplasmic ATP (187);                                     |
| Alkylation agent    | • Producing highly reactive alkylated groups, interacting with DNA and protein, inhibiting cell proliferation, and inducing cell apoptosis (189, 190). | • Cardiomyocytes energy alteration (191).                   |
| ICI (Immune checkpoint inhibitors) | • Inducing anti-cancer response by targeting PD-1/PD-L1, CTLA-4 of T cells (192, 193). | • Myocarditis, pericardial effusion, arrhythmias, acute coronary syndrome, vasculitis (194). |
| TKI (Tyrosine Kinase Inhibitor) | • Target BCR-ABL (breakpoint cluster region-Abelson leukemia virus) tyrosine kinases (195). | • Sex-related: Males are more sensitively to cardiac toxicity than females (172), and females’ hearts showed more fibrosis (173); |
| PI (Protease Inhibitor) | • Binds selectively and irreversibly to the constitutive proteasome and immunoproteasome (196). | • Affect Cxs (Connexins) 43 and 26 and induce cardiomyopathy (172). |
| ADC (Antibody Drug Conjugates) | • Combined some cytotoxic drugs with a specific antibody to mediate specific anti-cancer effects (198):  
|                     | HER2 (human-epidermal growth factor receptor 2)                                         | • The mechanisms are not very clear;                        |
|                     | C-MET (cellular mesenchymal epithelial transition factor)                              | • Hypothesis: NF-kB signaling induced apoptosis (196);      |
|                     | EGFR (epidermal growth factor receptor)                                                 | • Hypothesis: Down-regulate autophagy and nitric oxide homeostasis (197). |
|                     | TROP-2 (Troponil Cell-Surface Antigen 2)                                                | • Inhibition of signal transduction, neangiogenesis, and repair of DNA damage (199); |
|                     | CD30 (TNF receptor superfamily member 8)                                                | • Disrupting ErbB2/ErbB4 (erb-b2 receptor tyrosine kinase 2/erb-b2 receptor tyrosine kinase 4) and NRG-1 (neuregulin 1) signaling pathway (200). |
| Bispecific antibodies | • Target two or more kinds of sites by cell bridging method (201):  
|                     | • Anti – VEGF and anti-EGF (anti-epidermal growth factor) (202), anti-DLL4 (anti-delta like canonical Notch ligand 4) and anti-VEGF (203),  
|                     | • Anti-HER2/CD3 (anti-HER2/CD3 T cell-dependent antibodies) (204),  
|                     | • Anti-C-MET and anti-PD1 (205), Anti-C-MET and anti-PD1 (206),  
|                     | • Anti-HER2 and anti-PD1 (anti-PD1)  
|                     | • Anti-CD29 (anti-integrin subunit beta 1) and anti-CD73 (anti-Ecto-5’-Nucleotidase) (209). | • CRS (Cytokine Release Syndrome) and TLS (Tumor Lysis Syndrome) (210, 211). |

angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), β-blockers, diuretics, and calcium channel blockers (CCBs) caused 5–10% cancer risk or cancer-related death (212). However, in the other two meta-analyses, data showed an uncertain result. In type 2 DM, the overall occurrence of cancer was negatively related to losartan [odds ratio (OR) 0.78, 95% CI 0.63–0.97], but was positively related to candesartan (OR 1.79, 95% CI 1.05–3.06) and telmisartan (OR 1.54, 95% CI 0.97–2.43) (213). Although aspirin was reported to prevent adverse events in CV diseases (214), low-dose aspirin in a low–medium CV risk population was not associated with a lower cancer incidence (215). The mechanisms of aspirin are different in CV diseases and cancer. Antiplatelet effects are the prominent mechanism of aspirin in CV diseases, while cyclooxygenase-dependent and independent mechanisms play the leading roles in cancer (216). Compared with control, low-dose aspirin was related to markedly higher sensitivity for detecting advanced colorectal neoplasms (217). In this review, we listed several main cardiovascular drugs and cancer risk mechanisms in Table 3.

**Summary**

This review discussed the relationships between heart failure and cancer from active exposure to passive adaption. People...
TABLE 3 Cardiovascular disease treatment and cancer risk.

| Research | Observation region | Cohort design | Treatments | Cancer type | Cancer risk/Prognosis /Mechanisms |
|----------|--------------------|---------------|------------|-------------|-----------------------------------|
| Jinhui Li (218) | Hong Kong | 6592 anti-hypertensives users and 84,116 anti-hypertensives users with aspirin | Anti-hypertensives (ACEi/ARB, CCB, β-blocker, α-blocker) and (or) aspirin | Lung cancer | Reducing the risk of lung cancer during the anti-hypertensives exposure period. |
| Seung-Hwa Lee (219) | Korea | 207,794 patients | ACEI, ARB | Lung cancer | No difference in lung cancer incidence between patients treatment with ACEI and patients treatment with ARB |
| Diana R Engineer (220) | Houston | 262/454 patients | ACEILARB, BBs | Stage III to IV CRC | Exposure to a combination of ACEI/ARB + BB is related to increased survival, decreased hospitalizations, and reduced tumor progression in advanced colorectal cancer. |
| Shih-Yi Lin (221) | Taiwan | 22384 patient | ACEI, ARB | Lung cancer | Compared with ARB, ACEI increased the risk of lung cancer. Compared with non-ARB users, ARB users decreased the risk of lung cancer. |
| Phyo T Htoo (222) | US | 532 CRC/111,533 ACEI/ARB initiators | ACEI/ARB initiators | CRC | No association between ACEI/ARB initiation and the short-term CRC risk. |
| Oliver William Scott (223) | New Zealand (NZ) | 14,976 women | β-blocker | Breast cancer | BB-associated risk happened in the initial few months. Long-term BB use may be associated with a lower incidence of breast cancer. |
| Lina Jansen (224) | Germany | 1762 CRCs vs. 1708 controls | β-blocker | CRC | Beta-blocker use is not related to decreased risk of CRC. Long-term beta-blocker use and the risk of stage IV CRC have a positive relationship. |
| Lovisa Ekestubbe (225) | Sweden | 9254 patients | Metoprolol, atenolol, bisoprolol, and other beta-blockers. | CRC | No statistically significant difference in the risk of 90-day postoperative mortality between common β-blockers. |

actively select various lifestyles, such as smoking habits, anchor, diet, sleep, and physical activity. These would construct a specific internal environment to passively adapt to these stimuli and try to keep the balance of each individual by inducing various regulation systems, like the neuroendocrine system, immune system, gut microbiome, and intercellular molecules communication through microvesicle transportation. Besides, clinical treatments used in heart failure or cancer could also cause mutual interference with each other. The above series of outer exposures and inner system responses will help us better understand why these two complicated diseases always exist in a similar population and how to coordinate various treatments for both diseases. The best aim for curing heart failure or cancer is not only to reduce the side effect to the lowest level but also to reach a win–win situation for both heart failure and cancer.

Author contributions

YD contributed to the concept of review and wrote the manuscript. TW contributed to the concept of review and revised the manuscript. Both authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Natural Science Foundation of China (grant number: 81602136), the Natural Science Foundation of Ningbo (grant number: 2018A610394), and the Zhejiang Provincial Medical and Health Science Foundation (grant number: 2019KY613).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

1. Bertero E, Canepa M, Maack C, Amperi P. Linking heart failure to cancer: background evidence and research perspectives. Circulation. (2018) 138:735–42. doi: 10.1161/CIRCULATIONAHA.118.036306
2. Lam BQ, Srivastava R, Morvant J, Shankar S, Srivastava RK. Association of diabetes mellitus and alcohol abuse with cancer: molecular mechanisms and clinical significance. CellS. (2021) 1:3077. doi: 10.3390/cells10113077
3. Grubb AF, Greene SJ, Fudim M, Dewald T, Mentz RJ. Drugs of abuse and heart failure. J Card Fail. (2021) 27:1260–75.
4. Loeb EA, Ernter VL, Warner KE, Abbotts J, Laszlo J. Smoking and lung cancer: an overview. Cancer Res. (1984) 44:5940–58.
5. Macacu A, Apter P, Boniol M, Boyle P. Active and passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat. (2015) 154:213–24. doi: 10.1007/s10549-015-3628-4
6. Su B, Qin W, Xue F, Wei X, Guan Q, Jiang W, et al. The relation of passive smoking with cervical cancer: a systematic review and meta-analysis. Medicine (Baltimore). (2018) 97:e13601. doi: 10.1097/MD.0000000000013601
7. Jaim D, Chaudhary P, Varshney N, Bin Razak KS, Verma D, Khan Zahra TR, et al. Tobacco smoking and liver cancer risk: potential avenues for carcinogenesis. J Oncol. (2021) 2021:593537. doi: 10.1155/2021/593537
8. Morris PB, Ference BA, Jahangir E, Feldman DN, Ryan JJ, Brahimi H, et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the prevention of cardiovascular disease section leadership council and early career councils of the American college of cardiology. J Am Coll Cardiol. (2015) 66:1378–91. doi: 10.1016/j.jacc.2015.7.027
9. Sanner T, Grimsrud TK. Nicotine: carcinogenicity and effects on response to cancer treatment – a review. Front Oncol. (2015) 5:196. doi: 10.3389/fonc.2015.00196
10. Ambrose JA, Barusa RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. (2004) 43:1731–7. doi: 10.1016/j.jacc.2003.12.047
11. van Kruisjndijk RC, van der Graaf Y, Peeters PH, Visseren FL. Cancer risk in patients with manifest vascular disease: effects of smoking, obesity, and metabolic syndrome. Circulation. (2013) 128:2677–77. doi: 10.1161/CIRCULATIONAHA.112.003199
12. Gardner JD, Mouton AJ. Alcohol effects on cardiac function. Compr Physiol. (2015) 5:791–802. doi: 10.1002/cphy.c140046
13. Rumgay H, Murphy N, Ferrari P, Soerjomataram I. Alcohol and cancer: epidemiology and biological mechanisms. Nutrients. (2021) 13:3173. doi: 10.3390/nu13093173
14. Cattadori G, Segurini C, Picozzi A, Padeletti L, Anza C. Exercise and heart failure. Heart Fail Clin. (2018) 14:305–17. doi: 10.1016/j.pchf.2018.09.006
15. Aune D, Schlesinger S, Leitzmann MF, Tonstad S, Norat T, Riboli E, et al. Physical activity and the risk of heart failure: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. (2021) 36:367–81. doi: 10.1007/s10654-020-00993-6
16. McTierman AJ, Friedenreich CM, Kitzmayer PT, Powell KE, Macko R, Buchner D, et al. Physical activity in cancer prevention and survival: a systematic review. Med Sci Sports Exerc. (2019) 51:1252–61. doi: 10.1249/MSS.0000000000003197
17. Kushi LH, Doyle C, McCulloch M, Rock CL, Demark-Wahnefried W, Bandera EV, et al. American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. (2012) 62:50–67. doi: 10.3322/caac.20140
18. Dew MA, Hoch CC, Buyse DJ, Monk TH, Begley AA, Houck PR, et al. healthy older adults’ sleep predicts all-cause mortality at 6 to 19 years of follow-up. Psychosom Med. (2003) 65:83–73. doi: 10.1097/01.psy.0000073956.23250.7c
19. Irwin MR. Depression and insomnia in cancer: prevalence, risk factors, and effects on cancer outcomes. Curr Psychiatry Rep. (2013) 15:4004. doi: 10.1007/s11920-013-0404-4
20. Irwin MR. Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol. (2015) 66:143–72. doi: 10.1146/annurev-psych.011014-115285
21. Li Y, Zhang X, Winkelman JW, Redline S, Hu FB, Stamper M, et al. Association between Insomnia symptoms and mortality: a prospective study of U.S. Men. Circulation. (2014) 129:737–46. doi: 10.1161/CIRCULATIONAHA.113.004500
heart association and the heart failure society of America: this statement does not represent an update of the 2017 ACC/AHA/His heart failure guideline update. Circulation. (2019) 140:294–324. doi: 10.1161/CIRCULATIONAHA.118.038204
44. Kenny HC, Abdel ED. Heart failure in type 2 diabetes mellitus. Circ Res. (2019) 124:121–41. doi: 10.1161/CIRCRESAHA.118.313171
45. Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Med. (2017) 130:540–50. doi: 10.1016/j.amjmed.2017.04.010
46. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. (2008) 371:1513–8. doi: 10.1016/S0140-6736(08)60655-8
47. Drazner MH. The progression of hypertensive heart disease. Circulation. (2011) 123:327–34. doi: 10.1161/CIRCULATIONAHA.108.845792
48. Konraduraka G, Eckowski A, Rostoff P, Galicia-Latala D, Fruik W, Piwowarska W. Diabetes-Specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J. (2007) 28:2465–71. doi: 10.1093/eurheartj/ehm361
49. Horwich TB, Fonarow GC, Hamilton MA, Macellain WR, Woz MA, Tiltisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. (2008) 51:789–95. doi: 10.1016/j.jacc.2007.09.002
50. Tu H, Wen CP, Tsai SP, Chow WH, Wen C, Ye Y, et al. Cancer risk associated with chronic diseases and disease markers: prospective cohort study. BMJ. (2018) 360:k1344. doi: 10.1136/bmj.k1344
51. Stocks T, Van Hemelrijck M, Manjer J, Bjørge T, Ulmer H, Hallmans G, et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension. (2012) 59:902–10. doi: 10.1161/HYPERTENSIONAHA.111.189258
52. Gregor ME, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. (2011) 29:415–45. doi: 10.1146/annurev-immunol-031110-101322
53. Gerard C, Brown KA. Obesity and breast cancer – role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue. Mol Cell Endocrinol. (2008) 266:15–30. doi: 10.1016/j.mce.2007.09.014
54. Vansuun MN. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res. (2013) 19:1926–32. doi: 10.1158/1078-0432.CCR-12-0930
55. Gallagher EL, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. (2015) 95:727–48. doi: 10.1152/physrev.00030.2014
56. Renenhag AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-igf axis. Trends Endocrinol Metab. (2006) 17:328–36. doi: 10.1016/j.tem.2006.08.006
57. Basen-Engquist K, Chang M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep. (2011) 13:71–6. doi: 10.1007/s11912-010-0139-7
58. Ballatori P, Vicentini M, Manicardi V, Gallo M, Chiatamone Ranieri S, Grecei M, et al. Diabetes and risk of cancer incidence: results from a population-based cohort study in Northern Italy. BMC Cancer. (2017) 17:770. doi: 10.1186/s12885-017-3696-4
59. Keun N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst. (2015) 107:498. doi: 10.1093/jnci/dju428
60. Tee MC, Cao Y, Warrick GL, Hu FB, Chavarro JE. Effect of bariatric surgery on oncologic outcomes: a systematic review and meta-analysis. J Surg Oncol. (2013) 27:449–56. doi: 10.1002/jso.23105
61. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. (2015) 121:61–7. doi: 10.1172/JCI71140
62. Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure. Int J Mol Sci. (2019) 20:1698. doi: 10.3390/ijms20071698
63. Ino K, Shibata K, Kajiyama H, Yamamoto E, Nagasaka T, Nawa A, et al. Stress response pathway regulates DNA damage through Beta2-adrenoreceptors and its cardioprotective mechanisms: role of mitochondria and reactive oxygen species. Circ Res. (2019) 123:1481–7. doi: 10.1161/CIRCRESAHA.118.319247-X
64. Belli MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. (2011) 29:415–45. doi: 10.1146/annurev-immunol-031110-101322
65. Gerard C, Brown KA. Obesity and breast cancer – role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue. Mol Cell Endocrinol. (2008) 266:15–30. doi: 10.1016/j.mce.2007.09.014
66. Basen-Engquist K, Chang M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep. (2011) 13:71–6. doi: 10.1007/s11912-010-0139-7
67. Ballatori P, Vicentini M, Manicardi V, Gallo M, Chiatamone Ranieri S, Grecei M, et al. Diabetes and risk of cancer incidence: results from a population-based cohort study in Northern Italy. BMC Cancer. (2017) 17:770. doi: 10.1186/s12885-017-3696-4
68. Keun N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst. (2015) 107:498. doi: 10.1093/jnci/dju428
69. Tee MC, Cao Y, Warrick GL, Hu FB, Chavarro JE. Effect of bariatric surgery on oncologic outcomes: a systematic review and meta-analysis. J Surg Oncol. (2013) 27:449–56. doi: 10.1002/jso.23105
70. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. (2015) 121:61–7. doi: 10.1172/JCI71140
71. Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure. Int J Mol Sci. (2019) 20:1698. doi: 10.3390/ijms20071698
72. Ino K, Shibata K, Kajiyama H, Yamamoto E, Nagasaka T, Nawa A, et al. Stress response pathway regulates DNA damage through Beta2-adrenoreceptors and its cardioprotective mechanisms: role of mitochondria and reactive oxygen species. Circ Res. (2019) 123:1481–7. doi: 10.1161/CIRCRESAHA.118.319247-X
73. Belli MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. (2011) 29:415–45. doi: 10.1146/annurev-immunol-031110-101322
74. Gerard C, Brown KA. Obesity and breast cancer – role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue. Mol Cell Endocrinol. (2008) 266:15–30. doi: 10.1016/j.mce.2007.09.014
75. Basen-Engquist K, Chang M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep. (2011) 13:71–6. doi: 10.1007/s11912-010-0139-7
76. Ballatori P, Vicentini M, Manicardi V, Gallo M, Chiatamone Ranieri S, Grecei M, et al. Diabetes and risk of cancer incidence: results from a population-based cohort study in Northern Italy. BMC Cancer. (2017) 17:770. doi: 10.1186/s12885-017-3696-4
77. Keun N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst. (2015) 107:498. doi: 10.1093/jnci/dju428
Frontiers in Cardiovascular Medicine

Mir-92b is a novel biomarker of colorectal cancer at early stage. Int J Med Sci. 2021; 18:156. doi: 10.2217/fems.2021.156

AH, et al. Upregulation of Mir-17-92 cluster is associated with progression and cancer. J Transplant. 2019; 2019:225278. doi: 10.1155/2019/225278

Circulating exosomal Mir-19b-3p and Mir-101-3p as potential biomarkers for prostate cancer diagnosis and prognosis. Am J Cancer Res. 2021; 11:2802–20.

Deng H, Wang Y, Lu X, Xue S, Zhang L, Zhang Y, et al. Combined detection of Mir-21-5p, Mir-30a-3p, Mir-30a-5p, Mir-155-5p, Mir-216a and Mir-217 for screening of early heart failure diseases. Biosci Rep. 2020; 40:BSR20191653. doi: 10.1042/BSR20191653

He Q, Ye A, Ye W, Liao X, Qin G, Xu Y, et al. Cancer-secreted exosomal Mir-21-5p induces angiogenesis and vascular permeability by targeting Krt1. Cell Death Dis. 2021; 12:576. doi: 10.1038/s41419-021-03803-8

Soliman SE, Abdelallem AH, Alhnaify AM, Ibrahim RL, Elhadad ASA, Assar MFA. Circulating microRNA-22-5p and Mir-126b-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer. Mol Biol Rep. 2021; 48:5459–52. doi: 10.1007/s12053-021-06302-3

Esmadi SS, Nekouian R, Akbari A, Farajz A, Abbas A, Vagh A, Sahal G. Evaluation of circulating Mir-21 and Mir-322 as diagnostic biomarkers for gastric cancer. Cancer Res Ther. 2019. 15:115–9. doi: 10.4103/jcrt.jcrt_59_17

Hannafon BN, Trigoso YD, Calloway ZL, Yodd YM, Welm AL, et al. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res Treat. 2016; 1890:10.1007/s10549-016-4377-x

ParvizHamidi M, Haddad G, Ostadrakhimi S, Ostadrakhimi N, Sadeghi S, Feyaz S, et al. Circulating Mir-26a and Mir-21 as biomarkers for glioblastoma multiforme. Biotechnol Appl Biol Chem. 2019; 66:261–5. doi: 10.1002/bab.1707

Tusong H, Maolakuerban N, Guan J, Rixiati M, Wang WG, Arhati B, et al. Functional analysis of serum microRNAs Mir-21 and Mir-106a in colorectal cell carcinoma. Cancer Biomark. 2017; 18:79–85. doi: 10.3233/CBM-160676

Sierzega M, Kaczer M, Kolodziejczyk P, Kulig J, Sanak M, Richter P. Evaluation of serum microRNAs for breast cancer based on blood and tissue samples profiling: the importance of Mir-21 and Mir-311. Br J Cancer. 2017; 117:266–73. doi: 10.1038/bjc.2017.190

Garcia-Elias A, Tajes M, Yanez-Bube L, Enjaneus C, Comin-Colet J, Serra SA, et al. Atrial fibrillation in heart failure is associated with high levels of circulating microRNA-19a-5p and 22-5p and a defective regulation of intracellular calcium and cell-to-cell communication. Int J Mol Sci. 2021; 22:10377. doi: 10.3390/ijms221910377

Vadla GP, Daghat B, Patterson N, Ahmad V, Perez G, Garcia A, et al. Combining plasma extracellular vesicle Let-7b-5p, Mir-184 and Circulating Mir-22-3p levels for Nocle diagnosis and drug resistance prediction. Sci Rep. 2022; 12:6693. doi: 10.1038/s41598-022-10598-x

Diao ZB, Sun TX, Zong Y, Lin BC, Xia YS. Identification of plasma microRNA-22-3a as a marker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. J Int Med Res. 2020; 48:030006520967818. doi: 10.1177/030006520967818

van Boven N, Kardys I, van Vark LC, Akkerhuis KM, de Ronde MWJ, et al. Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. Eur J Heart Fail. 2018; 20:89–96. doi: 10.1002/ejhf.950

Yu Z, Rong Z, Sheng J, Luo Z, Zhang L, Li Y, et al. Aberrant non-coding RNA expressed in gastric cancer and its diagnostic value. Front Oncol. 2021; 11:606764. doi: 10.3389/fonc.2021.606764

Demolidi S, Doelebe C, Doddballapur A, Lang V, Fisslthaler B, Chavakis E, et al. MicroRNA-30a mediates anti-inflammatory effects of shear stress and KLF2 via repression of angiotensin 2. J Mol Cell Cardiol. 2015; 88:111–9. doi: 10.1016/j.yjmcc.2015.10.009
130. Duisters RF, Tijssen AJ, Schroot B, Leenders J, Lentink V, van der Made I, et al. Mir-133 and Mir-30 regulate connective tissue growth factor: implications for a role of mirnas in myocardial matrix remodeling. Circ Res. (2009) 104:170–8; 66 following 178. doi: 10.1161/CIRCRESAHA.108.182535.

131. Veitch S, Njock MS, Chandy M, Siraj MA, Chi L, Mak H, et al. Mir-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes. Cardiovasc Diabetol. (2022) 21:31. doi: 10.1186/s12933-022-01458-z.

132. Xu R, Liu S, Chen H, Lao L. MiR-33a-3p downregulation contributes to chemoresistance of osteosarcoma cells through activating bcl-1-mediated autophagy. Oncol Rep. (2010) 35:1577–63. doi: 10.3892/or.2015.4497.

133. Croset M, Pantano E, Kan CW, Bonelle Y, Descotes E, Alix-Panabieres C, et al. MiRNA-30 family members inhibit breast cancer invasion, osteosinamacy, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res. (2018) 78:5259–73. doi: 10.1158/0008-5472.CAN-17-3038.

134. Ochvinnikova ES, Schmiedt D, Veigler ET, Ter Meuten IM, Valente MA, Liu LC, et al. Signature of circulating micromeres in patients with acute heart failure. Eur J Heart Fail. (2016) 18:414–23. doi: 10.1002/ejhf.332.

135. Li M, Zhou Y, Xia T, Zhou X, Huang Z, Zhang H, et al. Circulating miRNAs from the Mir-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer. Breast Cancer Res Treat. (2018) 170:457–70. doi: 10.1007/s10549-018-4757-3.

136. Cheng Q, Feng E, Zhu L, Zheng Y, Luo X, Liu C, et al. Circulating Mir-106a is a novel prognostic and lymph node metastasis indicator for cholangiocarcinoma. Sci Rep. (2015) 5:16103. doi: 10.1038/srep16103.

137. Cochetti G, Poli G, Guelli G, Boni A, Egidio MG, Mearini E. Different levels of serum miRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. Onco Targets Ther. (2016) 9:7545–53. doi: 10.2147/OTT.S119027.

138. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Sci Transl Med. (2015) 7:304ra119. doi: 10.1126/scitranslmed.aab3347.

139. Mucosal Immunol. (2013) 6:612. doi: 10.1159/000443358.

140. Sygitowicz G, Tomaniak M, Błaszczyk O, Koltowski L, Filipiak KJ, Siidaśkiwicz D. Circulating microbionucleic acids Mir-1, Mir-21 and Mir-208a in patients with symptomatic heart failure: preliminary results. Arch Cardiovasc Dis. (2010) 103:634–42. doi: 10.1016/j.acvd.2010.02.003.

141. Grega V, Verbeek RA, Heinsen FA, Ruhlemann MC, Spehlmann ME, Cruz FD, et al. Circulating Mir-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. Oncotarget. (2017) 8:9994–7002. doi: 10.18632/oncotarget.14355.

142. Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA. The application of ecological theory toward an understanding of the human microbiome. Science. (2013) 325:1255–62. doi: 10.1126/science.1224203.

143. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. (2012) 13:484–90. doi: 10.1038/nrg3182.

144. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Nutritional ecology of the gut: insights from a metaorganismal perspective. J Nutr. (2011) 144:646–74. doi: 10.1016/j.jnut.2011.04.001.

145. De Santis S, Cavalcanti E, Mastronardi M, Jirillo E, Chieppa M. Nutritional interaction between host and gut microbiota and its products. Nat Rev Microbiol. (2017) 15:465–78. doi: 10.1038/nrmicro.2017.44.

146. Vaishnava S, Behrendt CL, Ismail AS, Eckmann L, Hooper LV. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbe interface. Proc Natl Acad Sci USA. (2015) 112:8541–6. doi: 10.1073/pnas.1506553112.

147. Petersen LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. (2014) 14:141–53. doi: 10.1038/nri3668.

148. Chung WS, Walker AW, Louis P, Parkhill J, Vermeiren J, Bossche D, et al. Modulation of the human gut microbiota by dietary fibres occurs at the species level. BMC Biol. (2016) 14:3. doi: 10.1186/s12915-015-0224-3.

149. Sommer F, Backhed F. The gut microbiota engages different signaling pathways to induce duox2 expression in the ileum and colon epithelium. Mucosal Immunol. (2015) 8:372–9. doi: 10.1038/mi.2014.74.

150. Trostel M, Andersen GO, Broch K, Hov JR. The gut microbiome in coronary artery disease: heart failure current knowledge and future directions. EBioMedicine. (2020) 52:102649. doi: 10.1016/j.ebiom.2020.102649.
Malignant, 12:792751. doi: 10.1159/000462402.2019.1914954.

206. Wei X, Juan ZX, Min FX, Nan C, Hua ZX, Qing FZ, et al. Recombinant immunotoxin Anti-C-Met/Pe3Skedel inhibits proliferation and promotes apotosis of gastric cancer cells. J Exp Clin Cancer Res. (2011) 30:67. doi: 10.1186/1756-9966-30-67.

207. Jeong S, Park E, Kim HD, Sung E, Kim H, Jeon J, et al. Novel Anti-4- 1bpa-L1 Bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. J Immunother Cancer. (2021) 9:e002428. doi: 10.1002/jtc2.2021-002428.

208. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, et al. Target Arm affinities determine preclinical efficacy and safety of Anti-Her2/Cd4 bispecific antibody. JCI Insight. (2020) 5:e133757. doi: 10.1172/jci.insight.133757.

209. Yuan Q, Liang Q, Sun Z, Yuan X, Hou W, Yang Y, et al. Development of bispecific Anti-C-Met/Pd-1 antibodies for the treatment of solid tumors and the effect of C-Met binding affinity on combination cancer therapies. Oncotarget. (2021) 13:1544-52. doi: 10.1186/s13058-017-1673-6.

210. Darvishi B, Farahmand L, Jalili N, Majidzadeh AK. Blinatumomab provoked heart failure. Int Immunopharmacol. (2016) 41:42-6. doi: 10.1016/j.intimp.2016.10.017.

211. Krasowska S, Brzoska F, Stohlz F, von Bonn S, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. (2019) 23:89. doi: 10.1186/s13054-017-1678-1.

212. Sipahi I, Dehanne SM, Rowland DY, Simon DI, Fang JC. Angiogenesis- receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. (2010) 11:627-36. doi: 10.1016/S1470-2045(10)70106-6.

213. Bangalore S, Kumar S, Kjeldsen SE, Makanji H, Grossman E, Wettergren J, et al. Anti-angiogenic drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. (2016) 17:254-62. doi: 10.1016/S1470-2045(16)30030-4.

214. de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and drug therapy-related cardiotoxicity: a metabolic insight.133757.

215. Madonna R. Multi-target drugs for blood cancer in the elderly: implications of damage and repair in the cardiovascular toxicity. Front Physiol. (2021) 12:792751. doi: 10.3389/fphys.2021.792751.

216. Sculnalli E, Grammatico S, Vozella E, Petrucci MT. Proteasome inhibitors for the treatment of multiple myeloma. Expert Opin Pharmacother. (2018) 19:375-86. doi: 10.1080/14656566.2018.1441287.

217. Wu P, Oren O, Gertz MA, Yang EH. Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management. Crit Care. (2020) 23:66. doi: 10.1186/s13054-020-00961-w.

218. Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. (2016) 17:e254-62. doi: 10.1016/S1470-2045(16)30030-4.

219. Ponde NF, Lambertini M, de Azambuja E. Twenty years of Anti-Her2 therapy-associated cardiotoxicity. ESMO Open. (2016) 1:e000073. doi: 10.1136/esmoopen-2016-000073.

220. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in Her2-positive breast cancer. N Engl J Med. (2011) 365:1373-83. doi: 10.1056/NEJMoa0910383.
216. Thorat MA, Cuzick J. Role of aspirin in cancer prevention. Curr Oncol Rep. (2013) 15:533–40. doi: 10.1007/s11912-013-0351-3
217. Brenner H, Tao S, Haug U. Low-dose aspirin use and performance of immunochemical Fecal occult blood tests. JAMA. (2010) 304:2513–20. doi: 10.1001/jama.2010.1773
218. Li J, Lam ASM, Yau STY, Yiu KKL, Tsoi KKF. Antihypertensive treatments and risks of lung cancer: a large population-based cohort study in Hong Kong. BMC Cancer. (2021) 21:1202. doi: 10.1186/s12885-021-03971-6
219. Lee SH, Chun KL, Park J, Kim J, Sung JD, Park BW, et al. Angiotensin Converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea. Sci Rep. (2021) 11:18576. doi: 10.1038/s41598-021-97989-8
220. Engineer DR, Burney BO, Hayes TG, Garcia JM. Exposure to Acei/Arb and Beta-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Transl Oncol. (2013) 6:539–45. doi: 10.1593/tho.13346
221. Lin SY, Lin CL, Lin CC, Hsu WH, Lin CD, Wang IK, et al. Association between angiotensin-converting enzyme inhibitors and lung cancer—a nationwide, population-based, propensity score-matched cohort study. Cancers (Basel). (2020) 12:747. doi: 10.3390/cancers12070747
222. Htoo PT, Sturmer T, Jonsson-Funk M, Pate V, Simpson RJ Jr., Lund JL. Renin-angiotensin-aldosterone system-based antihypertensive agents and the risk of colorectal cancer among medicare beneficiaries. Epidemiology. (2019) 30:867–75. doi: 10.1097/EDE.0000000000001065
223. Scott OW, Tin Tin S, Elwood JM, Cavadino A, Habel LA, Kuper-Hommel M, et al. Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study. Breast Cancer Res Treat. (2022) 193:225–35. doi: 10.1007/s10549-022-06528-0
224. Jansen L, Below J, Chang-Claude J, Brenner H, Hoffmeister M. Beta blocker use and colorectal cancer risk: population-based case-control study. Cancer. (2012) 118:3911–9. doi: 10.1002/cncr.26727
225. Groves JS, Smail JM. Outbreak of superficial keratitis in rubber workers. Br J Ophthalmol. (1969) 53:683–7. doi: 10.1136/bjo.53.10.683